Evidence map›Paper›PMID 14996816›Full record

ArticleJournal of bacteriology2004

Antibiotic-sensitive TolC mutants and their suppressors.

Anne Marie Augustus, Teresa Celaya, Fasahath Husain, Matthew Humbard, Rajeev Misra

Abstract read
In one paragraph

Article in Journal of bacteriology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Effects of pleiotropicJournal of bacteriology · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Small Molecule Condensin Inhibitors.ACS infectious diseases · 2018
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Comprehensive identification of translation start sites by tetracycline-inhibited ribosome profiling.DNA research : an international journal for rapid publication of reports on genes and genomes · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anne Marie AugustusDepartment of Chemistry and Biochemistry, Arizona State University, Tempe, Arizona 85287, USA.
Teresa Celaya
Fasahath Husain
Matthew Humbard
Rajeev Misra

Funding

TARGETING AND ASSEMBLY OF E COLI OUTER MEMBRANE PROTEINSR01GM048167 · NIGMS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MISRA, RAJEEV · 1997 to 2011
$2.4M
Export &Import of Lethal Agents Mediated by TolCR01GM066988 · NIGMS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI MISRA, RAJEEV · 2003 to 2006
$881k
NIGMS NIH HHS R01 GM048167NIGMS NIH HHS R01 GM066988NIGMS NIH HHS R01-GM066988NIGMS NIH HHS R01-GM48167
6 · The paper itself

Abstract

The TolC protein of Escherichia coli, through its interaction with AcrA and AcrB, is thought to form a continuous protein channel that expels inhibitors from the cell. Consequently, tolC null mutations display a hypersensitive phenotype. Here we report the isolation and characterization of tolC missense mutations that direct the synthesis of mutant TolC proteins partially disabled in their efflux role. All alterations, consisting of single amino acid substitutions, were localized within the periplasmic alpha-helical domain. In two mutants carrying an I106N or S350F substitution, the hypersensitivity phenotype may be in part due to aberrant TolC assembly. However, two other alterations, R367H and R390C, disrupted efflux function by affecting interactions among the helices surrounding TolC's periplasmic tunnel. Curiously, these two TolC mutants were sensitive to a large antibiotic, vancomycin, and exhibited a Dex(+) phenotype. These novel phenotypes of TolC(R367H) and TolC(R390C) were likely the result of a general influx of molecules through a constitutively open tunnel aperture, which normally widens only when TolC interacts with other proteins during substrate translocation. An intragenic suppressor alteration (T140A) was isolated from antibiotic-resistant revertants of the hypersensitive TolC(R367H) mutant. T140A also reversed, either fully (R390C) or partially (I106N and S350F), the hypersensitivity phenotype of other TolC mutants. Our data suggest that this global suppressor phenotype of T140A is the result of impeded antibiotic influx caused by tapering of the tunnel passage rather than by correcting individual mutational defects. Two extragenic suppressors of TolC(R367H), mapping in the regulatory region of acrAB, uncoupled the AcrR-mediated repression of the acrAB genes. The resulting overexpression of AcrAB reduced the hypersensitivity phenotype of all the TolC mutants. Similar results were obtained when the chromosomal acrR gene was deleted or the acrAB genes were expressed from a plasmid. Unlike the case for the intragenic suppressor T140A, the overexpression of AcrAB diminished hypersensitivity towards only erythromycin and novobiocin, which are substrates of the TolC-AcrAB efflux pump, but not towards vancomycin, which is not a substrate of this pump. This showed that the two types of suppressors produced their effects by fundamentally different means, as the intragenic suppressor decreased the general influx while extragenic suppressors increased the efflux of TolC-AcrAB pump-specific antibiotics.

Indexed as

Gene Expression Regulation, BacterialMutation, MissenseAnti-Bacterial AgentsBacterial Outer Membrane ProteinsErythromycinEscherichia coliEscherichia coli ProteinsMembrane Transport ProteinsMicrobial Sensitivity TestsModels, MolecularNovobiocinAnti-Bacterial AgentsBacterial Outer Membrane ProteinsErythromycinEscherichia coli ProteinsMembrane Transport ProteinsNovobiocintolC protein, E coli

Identifiers

PMID14996816
PMCPMC355985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.